{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:14:43Z","timestamp":1786637683555,"version":"build-2736575974"},"reference-count":44,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R33 AI141184"],"award-info":[{"award-number":["R33 AI141184"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cryptosporidiosis is a major cause of life-threatening diarrhea in children and chronic diarrhea in immunocompromised individuals. Our previous work identified pyrazolo[3,4-d]pyrimidine benzoxaborole (2) as an orally efficacious inhibitor of Cryptosporidium with a downside of relapse after 7 days post drug treatment. Here, we report a structure\u2013activity relationship study around the benzoxaborole ring of compound 2, resulting in rac-\u00a011 with improved in vitro potency (EC50 = 0.025 \u03bcM). Remarkably, rac-\u00a011 is noncytotoxic and displayed curative in vivo efficacy in Cryptosporidium-infected immunocompromised NSG mice. Furthermore, resolution of rac-11 into its enantiomers demonstrated that one enantiomer is 2-fold more potent (ent2-11; EC50 = 0.011 \u03bcM), whereas the other is 400-fold less potent, highlighting the importance of the methyl group at the C3 position of benzoxaborole. The ent2-11 also had reduced adverse binding to hPDE5 compared to 2. Collectively, these findings advance new and effective candidates for the treatment of cryptosporidiosis.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01707","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:10:50Z","timestamp":1785849050000},"page":"19355-19370","source":"Crossref","is-referenced-by-count":0,"title":["Structure\u2013Activity\nRelationship Study of Anti-\n                    <i>Cryptosporidium<\/i>\n                    Benzoxaboroles\nYields Enhanced Potency and\nCurative Efficacy"],"prefix":"10.1021","volume":"69","author":[{"given":"Soumitra","family":"Guin","sequence":"first","affiliation":[{"name":"Saint Louis University , , , ,","place":["Saint Louis, Missouri, United States, 63103"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose\u0301 E.","family":"Teixeira","sequence":"additional","affiliation":[{"name":"University of Vermont Larner College of Medicine , , , ,","place":["Burlington, Vermont, United States, 05401"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Miller","sequence":"additional","affiliation":[{"name":"University of Vermont Larner College of Medicine , , , ,","place":["Burlington, Vermont, United States, 05401"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Sarkar","sequence":"additional","affiliation":[{"name":"Saint Louis University , , , ,","place":["Saint Louis, Missouri, United States, 63103"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5393-139X","authenticated-orcid":true,"given":"Christopher D.","family":"Huston","sequence":"additional","affiliation":[{"name":"University of Vermont Larner College of Medicine , , , ,","place":["Burlington, Vermont, United States, 05401"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-619X","authenticated-orcid":true,"given":"Marvin J.","family":"Meyers","sequence":"additional","affiliation":[{"name":"Saint Louis University , , , ,","place":["Saint Louis, Missouri, United States, 63103"]},{"name":"Saint Louis University , , , ,","place":["St. Louis, Missouri, United States, 63103"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"1","key":"2026081311074194600_cit1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/17460441.2020.1812577","article-title":"Phenotypic screening techniques for","volume":"16","author":"Love","year":"2021","journal-title":"Expert Opin. Drug Discovery"},{"issue":"8","key":"2026081311074194600_cit2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-012540","article-title":"Safe and effective\ntreatments are needed for cryptosporidiosis, a truly neglected tropical\ndisease","volume":"8","author":"Gilbert","year":"2023","journal-title":"BMJ Global Health"},{"issue":"1","key":"2026081311074194600_cit3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1473-3099(14)70772-8","article-title":"A review of the\nglobal burden, novel diagnostics, therapeutics, and vaccine targets\nfor cryptosporidium","volume":"15","author":"Checkley","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"4","key":"2026081311074194600_cit4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2125.2007.02873.x","article-title":"Treatment\nof cryptosporidiosis in immunocompromised individuals: systematic\nreview and meta-analysis","volume":"63","author":"Abubakar","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026081311074194600_cit5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetpar.2024.110279","article-title":"Emerging therapeutic\navenues against Cryptosporidium: A comprehensive review","volume":"331","author":"Ali","year":"2024","journal-title":"Vet. Parasitol."},{"key":"2026081311074194600_cit6","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-9-195","article-title":"High dose prolonged\ntreatment with\nnitazoxanide is not effective for cryptosporidiosis in HIV positive\nZambian children: a randomised controlled trial","volume":"9","author":"Amadi","year":"2009","journal-title":"BMC Infect. Dis."},{"issue":"9888","key":"2026081311074194600_cit7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal\ndisease in infants and young children in developing countries (the\nGlobal Enteric Multicenter Study, GEMS): a prospective, case-control\nstudy","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"issue":"5","key":"2026081311074194600_cit8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QCO.0000000000000761","article-title":"Emerging treatment\noptions for cryptosporidiosis","volume":"34","author":"Love","year":"2021","journal-title":"Curr. Opin. Infect.\nDis."},{"issue":"12","key":"2026081311074194600_cit9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ijpara.2017.08.006","article-title":"Advances in bumped kinase inhibitors\nfor human and animal therapy for cryptosporidiosis","volume":"47","author":"Hulverson","year":"2017","journal-title":"Int. J. Parasitol."},{"issue":"7","key":"2026081311074194600_cit10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00147-18","article-title":"Therapeutic Efficacy\nof Bumped Kinase Inhibitor 1369 in a Pig Model of Acute Diarrhea Caused\nby Cryptosporidium hominis","volume":"62","author":"Lee","year":"2018","journal-title":"Antimicrob. Agents\nChemother."},{"issue":"6","key":"2026081311074194600_cit11","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1021\/acs.jmedchem.9b00069","article-title":"Development of 5-Aminopyrazole-4-carboxamide-based\nBumped-Kinase\nInhibitors for Cryptosporidiosis Therapy","volume":"62","author":"Huang","year":"2019","journal-title":"J.\nMed. Chem."},{"issue":"4","key":"2026081311074194600_cit12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02061-18","article-title":"Optimization\nof Methionyl tRNA-Synthetase\nInhibitors for Treatment of Cryptosporidium Infection","volume":"63","author":"Buckner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"issue":"563","key":"2026081311074194600_cit13","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba8412","article-title":"Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in\nmice by inhibiting parasite phenylalanyl-tRNA synthetase","volume":"12","author":"Vinayak","year":"2020","journal-title":"Sci. Transl Med."},{"issue":"14","key":"2026081311074194600_cit14","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target\nin malaria and cryptosporidiosis","volume":"116","author":"Baragan\u0303a","year":"2019","journal-title":"Proc. Natl.\nAcad. Sci. U.S.A."},{"issue":"770","key":"2026081311074194600_cit15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm8631","article-title":"Cryptosporidium\nlysyl-tRNA synthetase inhibitors define the interplay between solubility\nand permeability required to achieve efficacy","volume":"16","author":"Caldwell","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"2026081311074194600_cit16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10687-y","article-title":"Identification of\na potent benzoxaborole drug candidate for treating cryptosporidiosis","volume":"10","author":"Lunde","year":"2019","journal-title":"Nat. Commun."},{"issue":"517","key":"2026081311074194600_cit17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7161","article-title":"Metal-captured inhibition\nof pre-mRNA processing activity by CPSF3 controls Cryptosporidium\ninfection","volume":"11","author":"Swale","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"15","key":"2026081311074194600_cit18","doi-asserted-by":"publisher","first-page":"11729","DOI":"10.1021\/acs.jmedchem.1c01136","article-title":"Optimization\nof the Urea Linker of\nTriazolopyridazine MMV665917 Results in a New Anticryptosporidial\nLead with Improved Potency and Predicted hERG Safety Margin","volume":"64","author":"Oboh","year":"2021","journal-title":"J. Med. Chem."},{"issue":"7658","key":"2026081311074194600_cit19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium\nPI(4)K inhibitor is a drug candidate for cryptosporidiosis","volume":"546","author":"Manjunatha","year":"2017","journal-title":"Nature"},{"issue":"11","key":"2026081311074194600_cit20","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41564-024-01810-x","article-title":"Cryptosporidium PI(4)K inhibitor EDI048 is a gut-restricted\nparasiticidal agent to treat paediatric enteric cryptosporidiosis","volume":"9","author":"Manjunatha","year":"2024","journal-title":"Nat. Microbiol."},{"issue":"D1","key":"2026081311074194600_cit21","doi-asserted-by":"publisher","first-page":"D898","DOI":"10.1093\/nar\/gkab929","article-title":"VEuPathDB:\nthe eukaryotic pathogen, vector and host bioinformatics resource center","volume":"50","author":"Amos","year":"2022","journal-title":"Nucleic Acids Res."},{"issue":"8015","key":"2026081311074194600_cit22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-024-07466-1","article-title":"Transcriptional control\nof the Cryptosporidium life\ncycle","volume":"630","author":"Walzer","year":"2024","journal-title":"Nature"},{"issue":"1","key":"2026081311074194600_cit23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52658-y","article-title":"Identification\nof potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium\nparvum-infected immunocompromised male mice","volume":"15","author":"Ajiboye","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"2026081311074194600_cit24","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1021\/acs.jmedchem.4c02805","article-title":"Discovery of an Orally Efficacious\nPyrazolo[3,4-d]pyrimidine\nBenzoxaborole as a Potent Inhibitor of Cryptosporidium","volume":"68","author":"Gasonoo","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026081311074194600_cit25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.118224","article-title":"Benzoxaboroles in medicinal chemistry: A structure-guided\nperspective on next-generation therapeutics","volume":"301","author":"Nagar","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"2026081311074194600_cit26","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1016\/j.febslet.2012.07.058","article-title":"Boron-based phosphodiesterase\ninhibitors\nshow novel binding of boron to PDE4 bimetal center","volume":"586","author":"Freund","year":"2012","journal-title":"FEBS Lett."},{"issue":"26","key":"2026081311074194600_cit27","doi-asserted-by":"publisher","first-page":"10194","DOI":"10.1021\/jo7020373","article-title":"The Scope\nand Mechanism of Phosphonium-Mediated SNAr\nReactions in Heterocyclic Amides and Ureas","volume":"72","author":"Wan","year":"2007","journal-title":"J. Org. Chem."},{"issue":"19","key":"2026081311074194600_cit28","doi-asserted-by":"publisher","first-page":"13768","DOI":"10.1021\/acs.jmedchem.3c01194","article-title":"Expanding the Role of Boron in New\nDrug Chemotypes: Properties, Chemistry, Pharmaceutical Potential of\nHemiboronic Naphthoids","volume":"66","author":"Kazmi","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026081311074194600_cit29","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1128\/AAC.02460-12","article-title":"Drug repurposing\nscreen reveals FDA-approved inhibitors of human HMG-CoA reductase\nand isoprenoid synthesis that block Cryptosporidium parvum growth","volume":"57","author":"Bessoff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"2026081311074194600_cit30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013691118","article-title":"Boronic acid with\nhigh oxidative stability and utility in biological contexts","volume":"118","author":"Graham","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"2026081311074194600_cit31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/infdis\/jix247","article-title":"Necessity\nof Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium\nInfection","volume":"216","author":"Arnold","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"10","key":"2026081311074194600_cit32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003987","article-title":"A Proposed\nTarget Product Profile and Developmental\nCascade for New Cryptosporidiosis Treatments","volume":"9","author":"Huston","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"2026081311074194600_cit33","article-title":"Phosphodiesterase\nInhibitors","volume-title":"StatPearls","author":"Padda","year":"2025"},{"issue":"24","key":"2026081311074194600_cit34","doi-asserted-by":"publisher","first-page":"22134","DOI":"10.1021\/acs.jmedchem.4c02123","article-title":"Discovery\nand Optimization of Dihydroquinolin-2(1H)-ones\nas Novel Highly Selective and Orally Bioavailable Phosphodiesterase\n5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026081311074194600_cit35","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1021\/acs.jmedchem.3c01562","article-title":"Discovery and SAR Study\nof Boronic Acid-Based Selective PDE3B Inhibitors from a Novel DNA-Encoded\nLibrary","volume":"67","author":"Rowley","year":"2024","journal-title":"J. Med. Chem."},{"issue":"30","key":"2026081311074194600_cit36","doi-asserted-by":"publisher","first-page":"4518","DOI":"10.1021\/acs.biochem.8b00336","article-title":"Identification\nof a PDE4-Specific Pocket for the Design of Selective Inhibitors","volume":"57","author":"Feng","year":"2018","journal-title":"Biochemistry"},{"issue":"3","key":"2026081311074194600_cit37","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1128\/AAC.02075-13","article-title":"Validation of IMP dehydrogenase\ninhibitors\nin a mouse model of cryptosporidiosis","volume":"58","author":"Gorla","year":"2014","journal-title":"Antimicrob.\nAgents Chemother."},{"issue":"5","key":"2026081311074194600_cit38","doi-asserted-by":"publisher","first-page":"938","DOI":"10.4269\/ajtmh.2007.76.938","article-title":"Detection\nand quantification of Cryptosporidium\nin HCT-8 cells and human fecal specimens using real-time polymerase\nchain reaction","volume":"76","author":"Parr","year":"2007","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"5","key":"2026081311074194600_cit39","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1645\/0022-3395(2002)088[1014:STCPII]2.0.CO;2","article-title":"Susceptibility\nto Cryptosporidium\nparvum infections in cytokine- and chemokine-receptor knockout mice","volume":"88","author":"Campbell","year":"2002","journal-title":"J. Parasitol."},{"key":"2026081311074194600_cit40","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511545313.037","article-title":"Persistence\nin the population:\nepidemiology, transmission","volume-title":"Human Herpesviruses:\nBiology, Therapy, and Immunoprophylaxis","author":"Wald","year":"2007"},{"issue":"9","key":"2026081311074194600_cit41","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","article-title":"NOD\/SCID\/gamma(c)(null)\nmouse: an excellent recipient mouse model for engraftment of human\ncells","volume":"100","author":"Ito","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2026081311074194600_cit42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/0006-2952(86)90247-9","article-title":"Multiple\nmolecular forms of cyclic nucleotide phosphodiesterase in cardiac\nand smooth muscle and in platelets. Isolation, characterization, and\neffects of various reference phosphodiesterase inhibitors and cardiotonic\nagents.","volume":"35","author":"Weishaar","year":"1986","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"2026081311074194600_cit43","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1016\/S0022-5347(01)63299-3","article-title":"Effects of sildenafil\non the relaxation of human corpus\ncavernosum tissue in vitro and on the activities of cyclic nucleotide\nphosphodiesterase isozymes","volume":"159","author":"Ballard","year":"1998","journal-title":"J. Urol."},{"issue":"4","key":"2026081311074194600_cit44","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances\nin targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discovery"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01707","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/19355\/66288392\/acs.jmedchem.6c01707.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/15\/19355\/66288392\/acs.jmedchem.6c01707.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:16:36Z","timestamp":1786634196000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/15\/19355\/5234446\/Structure-Activity-Relationship-Study-of-Anti"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":44,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01707","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.10001946\/v1","asserted-by":"object"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}